|
Drug treatment registered at baseline (before change) by class |
|||||
| Monotherapy (n = 186) |
Co-therapy with 2 drugs (n = 150) |
Polytherapy (> 2 drugs) (n = 135) |
|||
|
|
|||||
| Drug |
N (%) |
Drugs |
N (%) |
Drugs |
N (%) |
|
|
|||||
| Haloperidol |
45 (24.2) |
Other typical/atypical |
15 (10.0) |
Haloperidol/other typicals/other AC |
11 (8.2) |
| Valproate |
31 (16.7) |
Haloperidol/Lithium |
12 (8.0) |
Haloperidol/other typicals/Valproate |
11 (8.2) |
| Lithium |
27 (14.5) |
Olanzapine/Valproate |
10 (6.7) |
Haloperidol/other typicals/Lithium |
8 (5.9) |
| Olanzapine |
19 (10.2) |
Risperidone/non-valproate AC |
10 (6.7) |
Other typicals/other AC/Lithium |
8 (5.9) |
| Other typical |
18 (9.7) |
Other typical/Valproate |
10 (6.7) |
Haloperidol/other typicals |
3 (2.2) |
| Risperidone |
16 (8.6) |
Risperidone/Lithium |
9 (6.0) |
Other typicals/Valproate/Lithium |
2 (1.5) |
| Other AC |
14 (7.6) |
2 typicals |
9 (6.0) |
Other combinations |
92 (68.1) |
| Quetiapine |
10 (5.4) |
Other typical/Lithium |
8 (5.3) |
||
| Other atypical |
6 (3.2) |
Haloperidol/Valproate |
8 (5.3) |
||
| Lithium/non-valproate AC |
8 (5.3) |
||||
| Olanzapine/Lithium |
7 (4.7) |
||||
| Haloperidol/non-valproate AC |
7 (4.7) |
||||
| Other combinations |
37 (24.7) |
||||
|
AC = Anticonvulsivants; | |||||
Bellantuono et al. BMC Psychiatry 2007 7:33 doi:10.1186/1471-244X-7-33 |
|||||